FINWIRES · TerminalLIVE
FINWIRES

Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral From Overweight, Adjusts PT to $119 From $109

By

Monopar Therapeutics (MNPR) has an average rating of buy and mean price target of $125.58, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles